Predictors of yearly influenza vaccination in hospitalized and community based patients
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ludwig E, Bonanni P, Rohde G, Sayiner A, Torres A. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev. 2012;21(123):57–65.
WHO position paper.Pneumococcal conjugate vaccine for childhood immunization - Wkly Epidemiol Rec 2007;82(12):93–104.
Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). Morb Mortal Wkly Rep. 2010;59(1):1102–6.
Prevention and control of influenza with vaccines. Recommendations of the advisory committee on immunization practices (ACIP), 2011. Morb Mortal Wkly Rep. 2011;60(1):1128–32.
Nuorti J, Whitney C, Centers for Disease Control and Prevention (CDC). Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine: recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep. 2010;59(1):1–18.
Influenza (Seasonal) [Internet]. World Health Organization. Influenza. Fact Sheet 211. 2009 [cited 20 February 2016]. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/
Nichol K, Margolis K, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med. 1994;331(12):778–84.
Bridges C, Thompson W, Meltzer M, Reeve G, Talamonti W, Cox N, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults. JAMA. 2000;284(13):1655.
Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13- valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥ 65 years: recommendations of the advisory committee on immunization practice (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822–5.
Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults. N Engl J Med. 2015;372(12):1114–25.
Influenza Vaccine [Internet]. Health.gov.mt . 2016 [cited 20 February 2016]. Available from: https://deputyprimeminister.gov.mt/en/phc/pchyhi/Pages/Influenza-Vaccine.aspx
Heimberger T, Chang H, Shaikh M, Crotty L, Morse D, Birkhead G. Knowledge and attitudes of healthcare workers about influenza: why are they not getting vaccinated? Infect Control Hosp Epidemiol. 1995;16(7):412–5.
Kuster S, Tuite A, Kwong J, McGeer A, Fisman D. Evaluation of coseasonality of influenza and invasive pneumococcal disease: results from prospective surveillance. PLoS Med. 2011;8(6):e1001042.
Nichol K. The additive benefits of influenza and pneumococcal vaccinations during influenza seasons among elderly persons with chronic lung disease. Vaccine. 1999;17:S91–3.
Xakellis G. Predictors of influenza immunization in persons over age 65. J Am Board Fam Med. 2005;18(5):426–33.
Asciak R, Balzan M, Buttigieg J. Predictors of seasonal influenza vaccination in chronic asthma. Multidiscip Respir Med. 2013;8(1):68.
Müller D, Szucs T. Influenza vaccination coverage rates in five european countries- a population based cross sectional analysis of two consecutive influenza seasons. Infection. 2007;35(5):308–19.